4.5 Article

Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity

Journal

PARKINSONISM & RELATED DISORDERS
Volume 21, Issue 10, Pages 1251-1255

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2015.07.021

Keywords

Parkinson's disease; Biomarkers; Diagnostics; Autonomic function; DJ-1

Funding

  1. Parkinson's UK [F-1201, K-1006]
  2. Elan Pharmaceuticals
  3. GE Healthcare
  4. Biogen-Idec
  5. GW Pharm
  6. Merk-Serono
  7. Novartis
  8. Genzyme-Sanofi
  9. Fiveprime
  10. Ironwood
  11. Synthon BV
  12. Vertex Pharmaceuticals
  13. MRC
  14. CBD Solutions
  15. Dystonia Society
  16. Britannia pharmaceuticals
  17. Parkinson's UK [F-1201] Funding Source: researchfish

Ask authors/readers for more resources

Introduction: There is an urgent need to identify robust biomarkers for Parkinson's disease (PD). Previous studies have shown changes in composition and secretion of saliva in patients with PD, including an increase in salivary DJ-1 concentration. Autonomic dysfunction is a known feature of PD and could contribute to abnormal salivary gland function. Methods: In this pilot cross-sectional study, characterisation of the saliva of 16 patients with PD and 22 age-matched controls was performed. Salivary DJ-1 concentration was measured with quantitative immunoblotting; total protein concentration with a BCA assay and spectrophotometry; amylase with an amylase activity assay; albumin with an ELISA and mucin concentration with periodic-acid Schiff staining of SDS-gels. Results: Patient saliva showed an increase in both total protein concentration (8.4 vs 5.0 mg/ml, p = 0.0002) and DJ-1 concentration (0.84 vs 0.42 mu g/ml, p = 0.001), but there was no difference in salivary DJ-1 after adjusting for total protein concentration. In patients, adjusted DJ-1 levels correlated with disease severity measured with the MDS-Unified Parkinson's Disease Rating Scale (p = 0.019). Patient saliva had elevated concentrations of amylase (127 vs 64 units/ml, p = 0.0005) and albumin (110 vs 474 mu/ml, p = 0.0003) but not mucins. Conclusions: This study suggests that the saliva of patients with PD is different in composition to that of healthy age-matched controls, supporting the notion that saliva may be a good candidate for biomarker discovery in PD. The specific differences suggest that major salivary glands and gingival crevicular fluid may both be sources of additional DJ-1 and protein in patient saliva. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available